BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30972874)

  • 1. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
    Del Bello A; Abravanel F; Alric L; Lavayssiere L; Lhomme S; Bellière J; Izopet J; Kamar N
    Transpl Infect Dis; 2019 Aug; 21(4):e13093. PubMed ID: 30972874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Elmasry S; Wadhwa S; Bang BR; Cook L; Chopra S; Kanel G; Kim B; Harper T; Feng Z; Jerome KR; Kahn JA; Saito T
    Gastroenterology; 2017 Feb; 152(3):550-553.e8. PubMed ID: 27838287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients.
    Pischke S; Greer M; Hardtke S; Bremer B; Gisa A; Lehmann P; Haverich A; Welte T; Manns MP; Wedemeyer H; Gottlieb J;
    Transpl Infect Dis; 2014 Apr; 16(2):333-9. PubMed ID: 24438577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.
    Lhomme S; DebRoy S; Kamar N; Abravanel F; Metsu D; Marion O; Dimeglio C; Cotler SJ; Izopet J; Dahari H
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31323954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
    Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
    Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribavirin for chronic hepatitis E virus infection in transplant recipients.
    Kamar N; Izopet J; Tripon S; Bismuth M; Hillaire S; Dumortier J; Radenne S; Coilly A; Garrigue V; D'Alteroche L; Buchler M; Couzi L; Lebray P; Dharancy S; Minello A; Hourmant M; Roque-Afonso AM; Abravanel F; Pol S; Rostaing L; Mallet V
    N Engl J Med; 2014 Mar; 370(12):1111-20. PubMed ID: 24645943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy.
    Mazzola A; Tran Minh M; Charlotte F; Hdiji A; Bernard D; Wendum D; Calmus Y; Conti F
    Transplantation; 2017 Sep; 101(9):2083-2087. PubMed ID: 28376032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
    Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
    Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?
    Naguib H; Abouelnaga SF; Elsayed MM
    Int Urol Nephrol; 2024 Jan; 56(1):217-222. PubMed ID: 37209238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
    Friebus-Kardash J; Eisenberger U; Ackermann J; Kribben A; Witzke O; Wenzel J; Rohn H; Fiedler M
    Transpl Infect Dis; 2019 Jun; 21(3):e13088. PubMed ID: 30929308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.
    Kamar N; Abravanel F; Behrendt P; Hofmann J; Pageaux GP; Barbet C; Moal V; Couzi L; Horvatits T; De Man RA; Cassuto E; Elsharkawy AM; Riezebos-Brilman A; Scemla A; Hillaire S; Donnelly MC; Radenne S; Sayegh J; Garrouste C; Dumortier J; Glowaki F; Matignon M; Coilly A; Figueres L; Mousson C; Minello A; Dharancy S; Rerolle JP; Lebray P; Etienne I; Perrin P; Choi M; Marion O; Izopet J;
    Clin Infect Dis; 2020 Aug; 71(5):1204-1211. PubMed ID: 31793638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation.
    Chaillon A; Sirinelli A; De Muret A; Nicand E; d'Alteroche L; Goudeau A
    J Heart Lung Transplant; 2011 Jul; 30(7):841-3. PubMed ID: 21515077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
    Londoño MC; Manzardo C; Rimola A; Ruiz P; Costa J; Forner A; Ambrosioni J; Agüero F; Laguno M; Lligoña A; Moreno A; Miró JM
    J Antimicrob Chemother; 2016 Nov; 71(11):3195-3201. PubMed ID: 27402009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
    Wahid B
    J Infect Public Health; 2020 Jan; 13(1):149-150. PubMed ID: 31235341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.
    Cordts SE; Schneble L; Schnitzler P; Wenzel JJ; Vinke T; Rieger S; Fichtner A; Tönshoff B; Höcker B
    Pediatr Nephrol; 2018 Jul; 33(7):1215-1225. PubMed ID: 29500631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.